Türkan Tüzün
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Türkan Tüzün has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Yeşim Uygun Kızmaz
Department of Infectious Diseases and Clinical Microbiology, Kartal Kosuyolu High Specialization Education and Research Hospital, Istanbul, Türkiye
3 shared publications - Mehmet Emirhan Işık
Univ Hlth Sci, Kosuyolu High Specializat Res & Training Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkiye
2 shared publications - Melike Törüyenler Coşkunpınar
Department of Infectious Diseases and Clinical Microbiology, Ankara University School of Medicine, Ankara, Türkiye
2 shared publications - Pelin Irkoren
Department of Infectious Diseases and Clinical Microbiology, Ünye State Hospital, Turkish Ministry of Health, Ordu, Türkiye
2 shared publications - Taliha Karakök
Department of Communicable Diseases and Early Warning, Republic of Türkiye Ministry of Health, General Directorate of Public Health, Ankara, Türkiye
2 shared publications - Yasemin Çakır Kıymaz
Department of Infectious Diseases and Clinical Microbiology, Sivas Cumhuriyet University Faculty of Medicine, Sivas, Turkiye
2 shared publications
Latest Publications
- Open Access
Association of SGLT2 Inhibitor Use with Glycosuria, Pyuria, Urinary Symptoms, and Significant Urine Culture Positivity in Adults with Type 2 Diabetes: A Prospective Cross-Sectional Study
Background and Objectives: Sodium–glucose cotransporter 2 (SGLT2) inhibitors increase urinary glucose excretion, but the relationship between glycosuria and findings supporting urinary tract infection (UTI) remains unclear. We evaluated associations of SGLT2 inhibitor use with glycosuria, pyuria, UTI-compatible symptoms, and significant urine culture positivity in adults with type 2 diabetes. Materials and Methods: This prospective cross-sectional study included 251 adults who reported using every agent in their current oral antidiabetic regimen for at least three months. Blood tests, urinalysis, and midstream urine culture were obtained at a single study visit. SGLT2 inhibitor users and nonusers were compared; contaminated cultures were excluded from culture-based analyses. Multivariable logistic regression examined factors associated with glycosuria and pyuria. Results: Overall, 108 participants (43.0%) used an SGLT2 inhibitor (dapagliflozin, n = 51; empagliflozin, n = 57). Glycosuria was more frequent among users than nonusers (69.4% vs. 39.9%; OR = 3.43; 95% CI, 2.02–5.82; p < 0.001). In multivariable analysis, SGLT2 inhibitor use (adjusted OR = 3.14; 95% CI, 1.75–5.63) and each 1% increase in HbA1c (adjusted OR = 1.56; 95% CI, 1.27–1.92) were independently associated with glycosuria. Pyuria and UTI-compatible symptoms did not differ between groups. Among 217 evaluable cultures, significant culture positivity was numerically higher among users, but the estimate was imprecise (9.5% vs. 4.1%; OR = 2.45; 95% CI, 0.79–7.57; p = 0.110). Symptomatic culture positivity was similar (4.2% vs. 4.1%; p = 1.000). Conclusions: SGLT2 inhibitor use and higher HbA1c levels were independently associated with glycosuria. The small number of culture-positive events precludes firm conclusions about culture-based outcomes; these analyses are exploratory and do not demonstrate the presence or absence of an association. Glycosuria alone should not be interpreted as an indicator of UTI.
Open AccessAssociation of SGLT2 Inhibitor Use with Glycosuria, Pyuria, Urinary Symptoms, and Significant Urine Culture Positivity in Adults with Type 2 Diabetes: A Prospective Cross-Sectional Study
Background and Objectives: Sodium–glucose cotransporter 2 (SGLT2) inhibitors increase urinary glucose excretion, but the relationship between glycosuria and findings supporting urinary tract infection (UTI) remains unclear. We evaluated associations of SGLT2 inhibitor use with glycosuria, pyuria, UTI-compatible symptoms, and significant urine culture positivity in adults with type 2 diabetes. Materials and Methods: This prospective cross-sectional study included 251 adults who reported using every agent in their current oral antidiabetic regimen for at least three months. Blood tests, urinalysis, and midstream urine culture were obtained at a single study visit. SGLT2 inhibitor users and nonusers were compared; contaminated cultures were excluded from culture-based analyses. Multivariable logistic regression examined factors associated with glycosuria and pyuria. Results: Overall, 108 participants (43.0%) used an SGLT2 inhibitor (dapagliflozin, n = 51; empagliflozin, n = 57). Glycosuria was more frequent among users than nonusers (69.4% vs. 39.9%; OR = 3.43; 95% CI, 2.02–5.82; p < 0.001). In multivariable analysis, SGLT2 inhibitor use (adjusted OR = 3.14; 95% CI, 1.75–5.63) and each 1% increase in HbA1c (adjusted OR = 1.56; 95% CI, 1.27–1.92) were independently associated with glycosuria. Pyuria and UTI-compatible symptoms did not differ between groups. Among 217 evaluable cultures, significant culture positivity was numerically higher among users, but the estimate was imprecise (9.5% vs. 4.1%; OR = 2.45; 95% CI, 0.79–7.57; p = 0.110). Symptomatic culture positivity was similar (4.2% vs. 4.1%; p = 1.000). Conclusions: SGLT2 inhibitor use and higher HbA1c levels were independently associated with glycosuria. The small number of culture-positive events precludes firm conclusions about culture-based outcomes; these analyses are exploratory and do not demonstrate the presence or absence of an association. Glycosuria alone should not be interpreted as an indicator of UTI.
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-8
Clinical and Microbiological Profile of Serratia spp. Isolates and an Exploratory Comparison of Antimicrobial Resistance by Acquisition Setting: A Two-Year Retrospective Study
Purpose: To describe the clinical and microbiological profile of Serratia spp. isolates recovered at a tertiary-care hospital and to explore whether resistance differed by the acquisition category recorded in the source data. Patients and Methods: We retrospectively reviewed 157 consecutive clinical isolates from 146 patients recovered from September 27, 2019, through September 27, 2021. The primary between-group analysis retained one first-listed isolate per patient (n=146); Fisher’s exact tests, odds ratios with 95% confidence intervals, and Holm adjustment across 12 antimicrobials were used. A generalized estimating equation analysis of all 157 isolates, clustered by patient, was performed as a sensitivity analysis. Results: Serratia marcescens accounted for 128/157 isolates (81.5%), and sputum or tracheal aspirate accounted for 86/157 (54.8%). Resistance was lowest for trimethoprim/sulfamethoxazole (2/157, 1.3%), gentamicin (6/157, 3.8%), amikacin (7/157, 4.5%), and meropenem (7/157, 4.5%), and highest for imipenem (27/157, 17.2%). In the patient-level analysis, 90 isolates were community-classified and 56 were hospital-classified. Ertapenem resistance was 6/90 (6.7%) versus 11/56 (19.6%; odds ratio 3.42, 95% CI 1.19– 9.86), but the comparison did not remain significant after Holm adjustment (nominal p=0.031; adjusted p=0.342). No antimicrobial showed a multiplicity-adjusted between-group difference. The clustered all-isolate analysis yielded the same overall interpretation. Conclusion: This study provides a historical local description of Serratia isolates collected in 2019– 2021. The acquisition-category comparisons were exploratory and did not identify a robust resistance difference after accounting for repeated isolates and multiple comparisons. These data should not be used alone to guide current empirical therapy.
- 1 September 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-8
Open AccessClinical and Microbiological Profile of Serratia spp. Isolates and an Exploratory Comparison of Antimicrobial Resistance by Acquisition Setting: A Two-Year Retrospective Study
Purpose: To describe the clinical and microbiological profile of Serratia spp. isolates recovered at a tertiary-care hospital and to explore whether resistance differed by the acquisition category recorded in the source data. Patients and Methods: We retrospectively reviewed 157 consecutive clinical isolates from 146 patients recovered from September 27, 2019, through September 27, 2021. The primary between-group analysis retained one first-listed isolate per patient (n=146); Fisher’s exact tests, odds ratios with 95% confidence intervals, and Holm adjustment across 12 antimicrobials were used. A generalized estimating equation analysis of all 157 isolates, clustered by patient, was performed as a sensitivity analysis. Results: Serratia marcescens accounted for 128/157 isolates (81.5%), and sputum or tracheal aspirate accounted for 86/157 (54.8%). Resistance was lowest for trimethoprim/sulfamethoxazole (2/157, 1.3%), gentamicin (6/157, 3.8%), amikacin (7/157, 4.5%), and meropenem (7/157, 4.5%), and highest for imipenem (27/157, 17.2%). In the patient-level analysis, 90 isolates were community-classified and 56 were hospital-classified. Ertapenem resistance was 6/90 (6.7%) versus 11/56 (19.6%; odds ratio 3.42, 95% CI 1.19– 9.86), but the comparison did not remain significant after Holm adjustment (nominal p=0.031; adjusted p=0.342). No antimicrobial showed a multiplicity-adjusted between-group difference. The clustered all-isolate analysis yielded the same overall interpretation. Conclusion: This study provides a historical local description of Serratia isolates collected in 2019– 2021. The acquisition-category comparisons were exploratory and did not identify a robust resistance difference after accounting for repeated isolates and multiple comparisons. These data should not be used alone to guide current empirical therapy.
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 5771-5780
Complications and Antiviral Strategies in Herpes Zoster: A Retrospective Evaluation of 50 Patients Treated in a Secondary Care Setting
Purpose: To evaluate clinical characteristics, antiviral treatment patterns, complication rates, and the role of vitamin B12 supplementation among patients with herpes zoster (HZ) managed in a secondary care setting. Patients and Methods: Fifty adults with clinically diagnosed HZ (July 2019–October 2020) were included. Demographics, comorbidities, dermatomal involvement, laboratory findings, antiviral therapy (acyclovir, valacyclovir, brivudine), vitamin B12 use, and complications were recorded. Patients were stratified by age (< 65 vs ≥ 65 years). Categorical variables were compared using chi-square or Fisher’s exact test, and continuous variables with t-test or Mann–Whitney U-test. Ninety-five percent confidence intervals (CIs) were calculated. Results: The mean age was 63 ± 16 years, and 58% of patients were female. Diabetes and hypertension were the most common comorbidities. All patients received antiviral therapy within 72 hours of symptom onset. Postherpetic neuralgia (PHN) occurred in 8% of patients, and 2% developed secondary bacterial infection. Complication rates were 0% with acyclovir, 5.3% with valacyclovir, and 21.1% with brivudine (p = 0.112). No statistically significant difference in complication rates was observed between patients who received vitamin B12 and those who did not (p = 1.00). Complications occurred more frequently in patients aged ≥ 65 years compared with those < 65 years (16% vs 4%; p = 0.35). ALT levels were significantly lower in patients aged ≥ 65 years (p = 0.015). Conclusion: Early antiviral therapy was associated with a low incidence of PHN. Although brivudine was associated with a higher complication rate, causality cannot be established. The role of vitamin B12 remains uncertain. Larger prospective studies are warranted. Plain Language Summary: Shingles, also known as herpes zoster, is a painful rash caused by the reactivation of the chickenpox virus later in life. It most often affects older adults and people with chronic health conditions. The main complication is long-lasting nerve pain, called postherpetic neuralgia (PHN), which can greatly affect daily life. In this study, we reviewed the medical records of 50 patients treated for shingles at a secondary care hospital. All patients started antiviral therapy within three days of rash onset, and most also received pain medications. Vitamin B12 was prescribed for some patients, reflecting common practice in our country. We found that only 8% of patients developed PHN and 2% had a bacterial skin infection. Patients who received brivudine appeared to have more complications compared with those treated with acyclovir or valacyclovir, but the difference was not statistically significant. Vitamin B12 supplementation did not appear to change outcomes. These findings suggest that starting antiviral treatment early may help lower the risk of long-term nerve pain after shingles. However, since this was a small, single-center study, the results should be interpreted with caution. Larger studies are needed to confirm these findings and to clarify whether additional treatments, such as vitamin B12, play a role in preventing complications.
- 1 November 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 5771-5780
Open AccessComplications and Antiviral Strategies in Herpes Zoster: A Retrospective Evaluation of 50 Patients Treated in a Secondary Care Setting
Purpose: To evaluate clinical characteristics, antiviral treatment patterns, complication rates, and the role of vitamin B12 supplementation among patients with herpes zoster (HZ) managed in a secondary care setting. Patients and Methods: Fifty adults with clinically diagnosed HZ (July 2019–October 2020) were included. Demographics, comorbidities, dermatomal involvement, laboratory findings, antiviral therapy (acyclovir, valacyclovir, brivudine), vitamin B12 use, and complications were recorded. Patients were stratified by age (< 65 vs ≥ 65 years). Categorical variables were compared using chi-square or Fisher’s exact test, and continuous variables with t-test or Mann–Whitney U-test. Ninety-five percent confidence intervals (CIs) were calculated. Results: The mean age was 63 ± 16 years, and 58% of patients were female. Diabetes and hypertension were the most common comorbidities. All patients received antiviral therapy within 72 hours of symptom onset. Postherpetic neuralgia (PHN) occurred in 8% of patients, and 2% developed secondary bacterial infection. Complication rates were 0% with acyclovir, 5.3% with valacyclovir, and 21.1% with brivudine (p = 0.112). No statistically significant difference in complication rates was observed between patients who received vitamin B12 and those who did not (p = 1.00). Complications occurred more frequently in patients aged ≥ 65 years compared with those < 65 years (16% vs 4%; p = 0.35). ALT levels were significantly lower in patients aged ≥ 65 years (p = 0.015). Conclusion: Early antiviral therapy was associated with a low incidence of PHN. Although brivudine was associated with a higher complication rate, causality cannot be established. The role of vitamin B12 remains uncertain. Larger prospective studies are warranted. Plain Language Summary: Shingles, also known as herpes zoster, is a painful rash caused by the reactivation of the chickenpox virus later in life. It most often affects older adults and people with chronic health conditions. The main complication is long-lasting nerve pain, called postherpetic neuralgia (PHN), which can greatly affect daily life. In this study, we reviewed the medical records of 50 patients treated for shingles at a secondary care hospital. All patients started antiviral therapy within three days of rash onset, and most also received pain medications. Vitamin B12 was prescribed for some patients, reflecting common practice in our country. We found that only 8% of patients developed PHN and 2% had a bacterial skin infection. Patients who received brivudine appeared to have more complications compared with those treated with acyclovir or valacyclovir, but the difference was not statistically significant. Vitamin B12 supplementation did not appear to change outcomes. These findings suggest that starting antiviral treatment early may help lower the risk of long-term nerve pain after shingles. However, since this was a small, single-center study, the results should be interpreted with caution. Larger studies are needed to confirm these findings and to clarify whether additional treatments, such as vitamin B12, play a role in preventing complications.
- Open Access
- 27 March 2025
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 7 (1) , 58-65
Predictors for Publication of Specialty Theses in the Field of Infectious Diseases and Clinical Microbiology
The residency program of infectious diseases and clinical microbiology (IDCM) in Türkiye was started in 1983 by adopting the name IDCM. The IDCM program in Türkiye is a five-year program, including related clinical rotations. Presenting a thesis at the end of this program is mandatory. The first specialty thesis in the field of IDCM was
- 27 March 2025
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 7 (1) , 58-65
Open AccessPredictors for Publication of Specialty Theses in the Field of Infectious Diseases and Clinical Microbiology
The residency program of infectious diseases and clinical microbiology (IDCM) in Türkiye was started in 1983 by adopting the name IDCM. The IDCM program in Türkiye is a five-year program, including related clinical rotations. Presenting a thesis at the end of this program is mandatory. The first specialty thesis in the field of IDCM was
- Open Access
- 27 March 2024
- Published by Gumushane University in Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 13 (1) , 297-303
Erişkin Aşı Polikliniğine Başvuranlarda Aşılar Hakkındaki Bilgi, Tutum ve Davranışın Değerlendirilmesi
Bu çalışmada erişkin aşı polikliniğine başvuranların, erişkin aşılarıyla ilgili bilgi, tutum ve davranışlarının değerlendirilmesi amaçlanmıştır. Çalışmaya 2019 yılı Ekim ayı içerisinde Pamukkale Üniversitesi hastanesi erişkin aşı polikliniğine başvuran 18 yaş üstü gönüllü olan 208 kişi dahil edildi. Katılımcılara aşı hakkındaki bilgi, tutum ve davranışlarıyla ile ilgili sorularından oluşan anket formu uygulandı. Veriler SPSS 21.0 programında kullanılarak analiz edildi. İstatistiksel anlamlılık düzeyi p
- 27 March 2024
- Published by Gumushane University in Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 13 (1) , 297-303
Open AccessErişkin Aşı Polikliniğine Başvuranlarda Aşılar Hakkındaki Bilgi, Tutum ve Davranışın Değerlendirilmesi
Bu çalışmada erişkin aşı polikliniğine başvuranların, erişkin aşılarıyla ilgili bilgi, tutum ve davranışlarının değerlendirilmesi amaçlanmıştır. Çalışmaya 2019 yılı Ekim ayı içerisinde Pamukkale Üniversitesi hastanesi erişkin aşı polikliniğine başvuran 18 yaş üstü gönüllü olan 208 kişi dahil edildi. Katılımcılara aşı hakkındaki bilgi, tutum ve davranışlarıyla ile ilgili sorularından oluşan anket formu uygulandı. Veriler SPSS 21.0 programında kullanılarak analiz edildi. İstatistiksel anlamlılık düzeyi p
- Open Access
- 31 December 2023
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 17 (12) , 1682-1689
Rare complication spontaneous pneumothorax and pneumomediastinum in COVID-19 patients: A single center experience
Introduction: We aimed to describe the clinical characteristics and outcomes of patients with spontaneous pneumothorax (SPT) and pneumomediastinum (SPM) due to COVID-19 pneumonia. Methodology: This retrospective study evaluated inpatients at a COVID-19 pandemic hospital. Between March 11, 2020 and March 31, 2021, patients who developed complications of spontaneous pneumothorax (SPT) and pneumomediastinum (SPM) with a confirmed diagnosis of SARS-CoV-2 by polymerase chain reaction (PCR) method were included. Results: Of the 6,528 hospitalized patients, nine developed complications of SPT and SPM, with an incidence of 0.14%. Four of these patients developed SPT, one developed SPM, one developed SPT + SPM + emphysema, and three developed SPT + SPM. The mean age of the patients was 67.67 ± 13.41 years and the median was 68 (45-88) years. All patients were male. Six patients died, one of whom died of myocardial infarction from uncomplicated causes. Conclusions: Studies with more cases are needed to evaluate the causality between COVID-19 and pneumothorax (PT) and pneumomediastinum (PM). However, it should be kept in mind that PT and PM may lead to this clinic when sudden respiratory distress occurs in these patients and rapid diagnosis and treatment should be planned. As observed in this study, PT and PM are important factors in the development of mortality in COVID-19 patients.
- 31 December 2023
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 17 (12) , 1682-1689
Open AccessRare complication spontaneous pneumothorax and pneumomediastinum in COVID-19 patients: A single center experience
Introduction: We aimed to describe the clinical characteristics and outcomes of patients with spontaneous pneumothorax (SPT) and pneumomediastinum (SPM) due to COVID-19 pneumonia. Methodology: This retrospective study evaluated inpatients at a COVID-19 pandemic hospital. Between March 11, 2020 and March 31, 2021, patients who developed complications of spontaneous pneumothorax (SPT) and pneumomediastinum (SPM) with a confirmed diagnosis of SARS-CoV-2 by polymerase chain reaction (PCR) method were included. Results: Of the 6,528 hospitalized patients, nine developed complications of SPT and SPM, with an incidence of 0.14%. Four of these patients developed SPT, one developed SPM, one developed SPT + SPM + emphysema, and three developed SPT + SPM. The mean age of the patients was 67.67 ± 13.41 years and the median was 68 (45-88) years. All patients were male. Six patients died, one of whom died of myocardial infarction from uncomplicated causes. Conclusions: Studies with more cases are needed to evaluate the causality between COVID-19 and pneumothorax (PT) and pneumomediastinum (PM). However, it should be kept in mind that PT and PM may lead to this clinic when sudden respiratory distress occurs in these patients and rapid diagnosis and treatment should be planned. As observed in this study, PT and PM are important factors in the development of mortality in COVID-19 patients.
- 22 December 2023
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 28 (4) , 680-687
Evaluation of the Knowledge Level of Individuals Living in Denizli About Brucellosis
- 22 December 2023
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 28 (4) , 680-687
Evaluation of the Knowledge Level of Individuals Living in Denizli About Brucellosis
- 22 September 2023
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 28 (3) , 456-465
Analysis of Risk Factors Associated with Candidemia Among Patients with or without COVID-19 in Intensive Care Units During the Pandemic Process: A Multicenter Study
- 22 September 2023
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 28 (3) , 456-465
Analysis of Risk Factors Associated with Candidemia Among Patients with or without COVID-19 in Intensive Care Units During the Pandemic Process: A Multicenter Study
- Open Access
- 1 June 2022
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 35 (2) , 78-83
Evaluation of the Knowledge, Attitudes and Behaviors of Pregnant Women on Tetanus Vaccination
Objective: Tetanus, a vaccine-preventable disease, still has the potential to threaten human health. Immunization, especially in pregnant women, is critical as it protects both mother and baby. This study aims to evaluate the tetanus immunization status of pregnant women, their approach to the vaccine, and the factors affecting these.Methods: A 19-item questionnaire was applied to pregnant women from all over Turkey who applied to the hospital for any reason and agreed to participate.Results: A total of 5000 pregnant women from seven geographical regions, aged between 15 and 44 (mean 28 +/- 5.7) and whose gestational age was between 8 and 40 weeks (mean 22.07 +/- 8.5), participated in the study. %88.2 of them did not get vaccinated in their current pregnancy, and %23.2 of them didn't plan to get vaccinated. When the reasons for not being vaccinated were questioned, %28.6 and %15.4 of them were afraid of side effects and harming the baby, respectively. In addition, %23.9 of them thought they didn't need to be vaccinated, and %7.1 of them stated that the vaccine didn't provide any protection. In univariate analysis, regions, age, gestational week, and the number of pregnancies resulting in delivery were found as factors that statistically significantly affected getting vaccinated, but in multivariate analysis, gestational week, education until secondary school, being followed by a family physician, history of more than three pregnancies, and being vaccinated in a previous pregnancy was found as an independent factor.Conclusions: Neonatal tetanus should be prevented not only because of its high mortality but also, the sequelae, and it can be prevented, minimized, or even completely eradicated by vaccination of pregnant women. For this purpose, every pregnant woman should be informed, and education and counseling support should be provided for vaccina-tion against tetanus.
- 1 June 2022
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 35 (2) , 78-83
Open AccessEvaluation of the Knowledge, Attitudes and Behaviors of Pregnant Women on Tetanus Vaccination
Objective: Tetanus, a vaccine-preventable disease, still has the potential to threaten human health. Immunization, especially in pregnant women, is critical as it protects both mother and baby. This study aims to evaluate the tetanus immunization status of pregnant women, their approach to the vaccine, and the factors affecting these.Methods: A 19-item questionnaire was applied to pregnant women from all over Turkey who applied to the hospital for any reason and agreed to participate.Results: A total of 5000 pregnant women from seven geographical regions, aged between 15 and 44 (mean 28 +/- 5.7) and whose gestational age was between 8 and 40 weeks (mean 22.07 +/- 8.5), participated in the study. %88.2 of them did not get vaccinated in their current pregnancy, and %23.2 of them didn't plan to get vaccinated. When the reasons for not being vaccinated were questioned, %28.6 and %15.4 of them were afraid of side effects and harming the baby, respectively. In addition, %23.9 of them thought they didn't need to be vaccinated, and %7.1 of them stated that the vaccine didn't provide any protection. In univariate analysis, regions, age, gestational week, and the number of pregnancies resulting in delivery were found as factors that statistically significantly affected getting vaccinated, but in multivariate analysis, gestational week, education until secondary school, being followed by a family physician, history of more than three pregnancies, and being vaccinated in a previous pregnancy was found as an independent factor.Conclusions: Neonatal tetanus should be prevented not only because of its high mortality but also, the sequelae, and it can be prevented, minimized, or even completely eradicated by vaccination of pregnant women. For this purpose, every pregnant woman should be informed, and education and counseling support should be provided for vaccina-tion against tetanus.
- Open Access
- 8 August 2019
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 49 (4) , 1206-1211
Risk factors for community-onset urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli
Community-onset urinary tract infections(UTIs) caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli have increased in many parts of the world. This study aimed to determine the prevalence and risk factors for community-onset UTI caused by ESBL-producing E. coli. This prospective cohort study was conducted between January 2012 and March 2014 in cases of community-onset UTI caused by E. coli. Patients with UTI due to ESBL-producing E. coli and patients with UTI due to non-ESBL-producing E. coliwere compared to identify risk factors for ESBL-producing E. coli in the community. A total of 305 patients (116 males [46.4%]; mean age: 57.76 ± 18.06 years) were included in the study. Among these patients, 154 (50.5%) were infected with ESBL-producing E. coli. In multivariate analysis, the healthcare-associated UTI (odds ratio [OR]: 1.80; 95% confidence interval [CI]: 1.02–3.18; P = 0.041), upper urinary tract infection (OR: 3.05; 95% CI: 1.76–5.29; P < 0.0001), use of antibiotics in the preceding 6 months (OR: 2.28; 95% CI: 1.21–4.30; P = 0.011), and having two or more risk factors (OR: 4.03; 95% CI: 1.73–9.35; P = 0.001) were the significant factors associated with increased risk of community-onset UTIs due to ESBL-producing E. coli. The increasing prevalence ofESBL-producing E. coli makes it difficult to decide the empirical therapy in UTIs, especially in patients with two or more of the risk factors. A better understanding of the epidemiology and risk factors associated with community-onset UTIs due to ESBL-producing E. coli may have significant implications in decision-making for empirical antimicrobial treatment.
- 8 August 2019
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 49 (4) , 1206-1211
Open AccessRisk factors for community-onset urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli
Community-onset urinary tract infections(UTIs) caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli have increased in many parts of the world. This study aimed to determine the prevalence and risk factors for community-onset UTI caused by ESBL-producing E. coli. This prospective cohort study was conducted between January 2012 and March 2014 in cases of community-onset UTI caused by E. coli. Patients with UTI due to ESBL-producing E. coli and patients with UTI due to non-ESBL-producing E. coliwere compared to identify risk factors for ESBL-producing E. coli in the community. A total of 305 patients (116 males [46.4%]; mean age: 57.76 ± 18.06 years) were included in the study. Among these patients, 154 (50.5%) were infected with ESBL-producing E. coli. In multivariate analysis, the healthcare-associated UTI (odds ratio [OR]: 1.80; 95% confidence interval [CI]: 1.02–3.18; P = 0.041), upper urinary tract infection (OR: 3.05; 95% CI: 1.76–5.29; P < 0.0001), use of antibiotics in the preceding 6 months (OR: 2.28; 95% CI: 1.21–4.30; P = 0.011), and having two or more risk factors (OR: 4.03; 95% CI: 1.73–9.35; P = 0.001) were the significant factors associated with increased risk of community-onset UTIs due to ESBL-producing E. coli. The increasing prevalence ofESBL-producing E. coli makes it difficult to decide the empirical therapy in UTIs, especially in patients with two or more of the risk factors. A better understanding of the epidemiology and risk factors associated with community-onset UTIs due to ESBL-producing E. coli may have significant implications in decision-making for empirical antimicrobial treatment.